Adding the clinical framing, because it changes how the question reads.
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:
- NT-proBNP: 74 pg/mL (normal, cardiac function preserved)
- Lp(a): 54 nmol/L (genetic, unchanged — expected)
- ApoB: dropped from 159 to 99 mg/dL (excellent response)
- Coronary calcium score: 0 (unchanged from baseline — reassuring)
The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.
LabKate said:NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 10 months of treatment.
The 5 criteria (and my journey):
- Waist circumference: 49" → 37" ✅ Resolved
- Triglycerides: 227 → 112 ✅ Resolved
- HDL: 33 → 59 ✅ Resolved
- Blood pressure: 147/97 → 120/74 ✅ Resolved
- Fasting glucose: 122 → 85 ✅ Resolved
Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.
One concrete data point for the thread. For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after LabKate’s answer:
What the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss?
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Carry on.